| Autor: |
Chun-Yan Lan, Jing Zhao, Fan Yang, Ying Xiong, Rong Li, Yu Huang, Jing Wang, Chang Liu, Xue-Han Bi, Hai-Hong Jin, Jin Meng, Wei-Hong Zhao, Li Zhang, Ya-Fei Wang, Min Zheng, Xin Huang |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Cell reports. Medicine. 3(7) |
| ISSN: |
2666-3791 |
| Popis: |
This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The median duration of response (DOR) has not been reached, and 61.3% of patients have a DOR of at least 8 months. The median progression-free survival (PFS) is 7.8 months, and the median overall survival (OS) has not been reached. The PD-L1-positive group has an ORR of 25.0%, whereas the PD-L1-negative group has an ORR of 92.9%. Treatment-related grade 3 or 4 adverse events (AEs) occur in 70.6% of patients, with the most common being hypertension (29.4%) and palmar-plantar erythrodysesthesia syndrome (29.4%). Anlotinib plus TQB2450 show promising antitumor activity and manageable toxicities in patients with platinum-resistant or -refractory ovarian cancer. A phase 3 randomized controlled trial to further validate our findings is ongoing. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
